Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06IXI
|
|||
| Former ID |
DIB019028
|
|||
| Drug Name |
BrP-LPA
|
|||
| Synonyms |
alpha-bromomethylene phosphonate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H40BrO6P
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCC(=O)OCC(CC(P(=O)(O)O)Br)O
|
|||
| InChI |
1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19?/m0/s1
|
|||
| InChIKey |
HLVKVWDSLLFMSX-OYKVQYDMSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysophosphatidic acid receptor 1 (LPAR1) | Target Info | Antagonist | [1] |
| Lysophosphatidic acid receptor 2 (LPAR2) | Target Info | Antagonist | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Gap junction | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Myometrial Relaxation and Contraction Pathways | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.